The parity paradigm: Can legislation help reduce the cost burden of oral anticancer medications?

Sheetal M. Kircher; Caitlin R. Meeker; Halla Nimeiri; Daniel M. Geynisman; S. Yousuf Zafar; Veena Shankaran; Jonas De Souza; Yu Ning Wong

doi:10.1016/j.jval.2015.10.005

The parity paradigm: Can legislation help reduce the cost burden of oral anticancer medications?

Sheetal M. Kircher^*, Caitlin R. Meeker, Halla Nimeiri, Daniel M. Geynisman, S. Yousuf Zafar, Veena Shankaran, Jonas De Souza, Yu Ning Wong

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.

Original language	English (US)
Pages (from-to)	88-98
Number of pages	11
Journal	Value in Health
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/j.jval.2015.10.005
State	Published - Jan 1 2016

Keywords

drug costs
neoplasms

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Health Policy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jval.2015.10.005

Cite this

@article{51677e70a8154cac869ea094f33c1ddf,

title = "The parity paradigm: Can legislation help reduce the cost burden of oral anticancer medications?",

abstract = "Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.",

keywords = "drug costs, neoplasms",

author = "Kircher, {Sheetal M.} and Meeker, {Caitlin R.} and Halla Nimeiri and Geynisman, {Daniel M.} and Zafar, {S. Yousuf} and Veena Shankaran and {De Souza}, Jonas and Wong, {Yu Ning}",

note = "Publisher Copyright: {\textcopyright} 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).",

year = "2016",

month = jan,

day = "1",

doi = "10.1016/j.jval.2015.10.005",

language = "English (US)",

volume = "19",

pages = "88--98",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Limited",

number = "1",

}

TY - JOUR

T1 - The parity paradigm

T2 - Can legislation help reduce the cost burden of oral anticancer medications?

AU - Kircher, Sheetal M.

AU - Meeker, Caitlin R.

AU - Nimeiri, Halla

AU - Geynisman, Daniel M.

AU - Zafar, S. Yousuf

AU - Shankaran, Veena

AU - De Souza, Jonas

AU - Wong, Yu Ning

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.

AB - Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.

KW - drug costs

KW - neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84957839682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957839682&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2015.10.005

DO - 10.1016/j.jval.2015.10.005

M3 - Article

C2 - 26797241

AN - SCOPUS:84957839682

SN - 1098-3015

VL - 19

SP - 88

EP - 98

JO - Value in Health

JF - Value in Health

IS - 1

ER -

The parity paradigm: Can legislation help reduce the cost burden of oral anticancer medications?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this